Entero Healthcare Solutions Limited has released its investor presentation for the second quarter of FY27. The company highlighted a strong organic growth momentum, outpacing industry growth, with revenue increasing by 34.7% YoY (LFL). EBITDA margin stood at 5.3% for the quarter. The presentation also detailed key financial highlights for both the quarter and the half-year ended September 30, 2026, alongside an overview of its operational and market strategies.
Entero Healthcare Solutions Presents Q2 FY27 Financials and Strategy
Entero Healthcare Solutions Limited has published its investor presentation for the second quarter of Fiscal Year 2027 (Q2 FY27), ending September 30, 2026. The document details the company’s financial performance and strategic developments, emphasizing continued strong organic growth and operational improvements.
Financial Performance Highlights
During Q2 FY27, Entero Healthcare Solutions reported a significant revenue growth of 34.7% year-on-year (YoY) on a Like-for-Like (LFL) basis. This growth is attributed to strong organic performance, which outpaced industry growth. The EBITDA margin for the quarter was reported at 5.3%, reflecting sustained improvement. The company also noted that for the first half of the year (H1 FY27), revenue on an LFL basis grew by 37.2% YoY, with an EBITDA margin of 5.2%.
Key financial highlights for H1 FY27 include a reported revenue growth of 35.4% YoY. Gross margin improved by 136 basis points (bps) to 11.5%, and EBITDA margin saw an improvement of 139 bps to 5.2%. Profit After Tax (PAT) margin was 2.8%. The company also reported Net Working Capital (NWC) days at 66 days, an improvement from 68 days in H1FY26. ROCE stood at 21.8% and ROE at 21.3%.
For Q2 FY27 specifically, reported revenue growth was 32.9% YoY, with an EBITDA margin of 5.3%. PAT margin was 2.9%, and NWC days were 64 days. ROCE improved to 22.0% and ROE to 22.4%.
Strategic Focus and Market Position
The presentation underscores Entero Healthcare’s strategy of focusing on organic growth while also leveraging inorganic expansion. The company has demonstrated a consistent track record of acquisitions, with 51 acquisitions since inception. It operates within the large and highly fragmented Indian healthcare products distribution market and expects to benefit from market consolidation. Entero is recognized as one of India’s largest and fastest-growing healthcare products distribution platforms.
The company’s differentiated business model offers comprehensive and integrated commercial and supply chain solutions. A proprietary technology platform with integrated business intelligence tools supports operations and enhances efficiencies in the healthcare products distribution ecosystem. Entero’s operational highlights for H1FY27 include outperforming market growth at 37.2% against an industry average (IPM) of 14.5%. It serves over 92,200+ retail customers and 2,900+ hospital customers, with a network of 148 warehouses and over 90,400+ SKUs handled.
The management commentary indicates that the company is on track to deliver comfortably against its full-year guidance, driven by strong operational performance and strategic initiatives.
Source: BSE
